PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
0.79
0.5–0.75x AXSM's 1.57. Martin Whitman would question if short-term obligations are sufficiently covered.
0.79
0.5–0.75x AXSM's 1.51. Martin Whitman might be concerned about coverage if a crisis hits.
0.76
0.75–0.9x AXSM's 0.89. Bill Ackman might want more safety or minimal liabilities.
No Data
No Data available this quarter, please select a different quarter.
-8.52
Both companies show negative short-term coverage. Martin Whitman would investigate if industry distress creates special situation opportunities.